Next 10 |
home / stock / sprcy / sprcy news
SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial Results demonstrated that combining SciSparc's CannAmide™ with Clearmind's MEAI has the potential to reduce alcohol consumption PR Newswire TEL AVIV, Israel , March 17, 2022 ...
SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases Research builds on studies with support from global experts in the field of small molecule drugs and gene editing PR Newswire TEL AVIV, Israel , March 10, 2022 ...
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals PR Newswire TEL AVIV, Israel , March 8, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the developm...
SciSparc to Present at Aegis Virtual Conference PR Newswire TEL AVIV, Israel , Feb. 22, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the centra...
SciSparc Presents New Leadership Lineup PR Newswire TEL AVIV, Israel , Jan. 27, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC) a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous...
SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110 The Dual-Site Study Will Be Conducted at the Hannover Medical School in Germany, and Israel's Tel-Aviv Sourasky Medical Center PR Newswire ...
SciSparc Exploring Psychedelics as Possible Avenue to Expand Its IP Portfolio PR Newswire TEL AVIV, Israel , Jan. 11, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to...
SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer's Disease The clinical trial will be conducted at The Israeli Alzheimer's Medical Center and will evaluate the safety, tolerability and efficacy of SCI-110 in patients with Alzheimer's ...
SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders Patent Extends Protection for its Novel Compounds and Methods Already granted in Australia and Japan PR Newswire TEL AVIV, Israel , Jan. 4, 2022 /PRNewswire/ -- ...
SciSparc Provides Updates Upon Conclusion of 2021 PR Newswire TEL AVIV, Israel , Dec. 29, 2021 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the cent...
News, Short Squeeze, Breakout and More Instantly...
SciSparc Company Name:
SPRCY Stock Symbol:
OTCMKTS Market:
SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial Results demonstrated that combining SciSparc's CannAmide™ with Clearmind's MEAI has the potential to reduce alcohol consumption PR Newswire TEL AVIV, Israel , March 17, 2022 ...
SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases Research builds on studies with support from global experts in the field of small molecule drugs and gene editing PR Newswire TEL AVIV, Israel , March 10, 2022 ...
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals PR Newswire TEL AVIV, Israel , March 8, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the developm...